STOCK TITAN

Veracyte, Inc. - VCYT STOCK NEWS

Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.

Veracyte, Inc. (symbol: VCYT) is a pioneering genomic diagnostics company dedicated to significantly enhancing patient care through innovative diagnostic solutions. The company specializes in developing and providing genomic diagnostic products and services that improve clinical outcomes by resolving the uncertainties inherent in traditional diagnostic methods.

Veracyte's core business revolves around creating tests that offer more accurate diagnoses without resorting to risky, costly, and often unnecessary surgeries. By employing top-tier scientific rigor, state-of-the-art tools, and the brightest minds in the field, Veracyte delivers diagnostic solutions that bring clarity and assurance to patients and physicians alike.

The company's product portfolio includes the Afirma analysis, Percepta, Envisia, and other cutting-edge diagnostic tests. These products are designed to tackle diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. Veracyte's diagnostic tests are distinguished by their ability to provide conclusive results where traditional methods fall short, thereby sparing patients from unnecessary surgical procedures.

Recent achievements highlight Veracyte's commitment to innovation and excellence. The company consistently introduces evidence that sets new standards in genomic tests, fundamentally altering current clinical practice norms. This commitment to scientific excellence ensures that Veracyte remains at the forefront of the genomic diagnostics industry.

Veracyte's impact extends beyond just clinical outcomes; it significantly influences the lives of both patients and physicians by offering a clearer path forward. Through continuous research, strategic partnerships, and an unwavering dedication to improving patient care, Veracyte stands out as a leader in the genomic diagnostics field.

Rhea-AI Summary

Veracyte (Nasdaq: VCYT) has announced that it will release its second quarter 2024 financial results after market close on Tuesday, August 6, 2024. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a general business update. Investors and interested parties can access the live webcast from Veracyte's website or via a provided link. A webcast replay will be available after the broadcast on the company's investor relations page. For those who prefer to join by phone, dial-in registration is available through a separate link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.34%
Tags
-
Rhea-AI Summary

Veracyte has unveiled new data at the ENDO 2024 conference showcasing the potential of their Afirma GRID tool in identifying aggressive thyroid tumors. The research suggests that molecular signatures can aid in distinguishing between non-aggressive and aggressive thyroid cancers, thus aiding personalized treatment plans. Key findings from three studies were presented. One study highlighted the high negative predictive value of certain molecular signatures in ruling out significant tumor invasion in over 50% of cases. Another study identified cancer-associated fibroblasts linked to aggressive tumor behavior. A third study detailed the variability of PSMA expression in aggressive thyroid nodules. These insights reinforce Veracyte's commitment to advancing thyroid cancer diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
-
Rhea-AI Summary

Veracyte (Nasdaq: VCYT) announced that data from three studies using the Afirma GRID tool will be presented at ENDO 2024, scheduled for June 1-4 in Boston. These studies aim to provide new molecular insights into thyroid tumors, potentially personalizing treatment further. Key presentations include research on mRNA expression in thyroid tumors, PSMA expression in thyroid nodules, and the correlation of cancer-associated fibroblasts with aggressive thyroid cancer behavior. These findings could help clinicians offer individualized care based on molecular characteristics of patients' tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
none
Rhea-AI Summary

Veracyte (Nasdaq: VCYT), a prominent cancer diagnostics firm, announced its participation in two upcoming investor conferences. The first is the Leerink Partners 2024 Healthcare Crossroads Conference in Austin, TX, where Veracyte will host a fireside chat on May 29th at 12:20 p.m. ET. The second is the William Blair 44th Annual Growth Stock Conference in Chicago, IL, with Veracyte presenting on June 4th at 5:40 p.m. ET. Live audio webcasts of these events will be available on Veracyte's investor relations website, with replays accessible following the live broadcasts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences
-
Rhea-AI Summary

Veracyte, Inc. (Nasdaq: VCYT) reported first quarter 2024 financial results, achieving $96.8 million in total revenue, a 17% increase from the previous year. The company experienced a 25% growth in testing revenue and expanded its clinical evidence for Decipher Prostate and Afirma tests. Veracyte acquired C2i Genomics to develop an MRD test, received Medicare coverage for Afirma TERT promoter gene mutation test, and secured a contract with a major U.S. commercial payer. The company improved net loss, raised full-year 2024 revenue guidance to $402-$410 million, and expects $236-$240 million in cash, cash equivalents, and short-term investments by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.33%
Tags
-
Rhea-AI Summary

Veracyte, Inc. presented data from 14 studies at AUA 2024 showing the effectiveness of Decipher Prostate and Decipher Bladder Genomic Classifiers in providing better prognostic information for patients with prostate and bladder cancer. The research-use-only Decipher GRID tool is also aiding in advancing scientific understanding of these diseases. The studies presented reinforce Veracyte's commitment to evidence-based tests and clinical utility. The Decipher Prostate test has shown the ability to better inform prostate cancer treatment, while the Decipher Bladder test is proving useful in predicting outcomes for bladder cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
none
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) will release its first quarter 2024 financial results on May 7, 2024, followed by a conference call and webcast to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
-
Rhea-AI Summary
Veracyte, Inc. announces new study results showing that the Decipher Prostate Genomic Classifier is prognostic for identifying prostate cancer progression among patients undergoing Active Surveillance. The test provides treatment-outcome data from a prospective trial, aiding in the selection of optimal candidates for active surveillance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
none
-
Rhea-AI Summary
Veracyte, Inc. announces that nine studies showcasing the value of Decipher Prostate and Decipher Bladder testing will be presented at AUA 2024, emphasizing the clinical utility and biological insights of these genomic classifiers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
none
Rhea-AI Summary
Veracyte, Inc. announced that its Decipher Prostate Genomic Classifier has received a 'Level 1B' evidence rating in the 2024 NCCN Clinical Practice Guidelines in Oncology, making it the only gene expression test to achieve this status. The test was recognized for its prognostic value in risk stratifying patients with localized prostate cancer, with recommendations based on extensive clinical evidence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none

FAQ

What is the current stock price of Veracyte (VCYT)?

The current stock price of Veracyte (VCYT) is $44.13 as of December 6, 2024.

What is the market cap of Veracyte (VCYT)?

The market cap of Veracyte (VCYT) is approximately 3.3B.

What does Veracyte, Inc. specialize in?

Veracyte, Inc. specializes in genomic diagnostics to improve patient care by resolving inconclusive results from traditional diagnostic methods.

What products does Veracyte offer?

Veracyte offers genomic diagnostic products such as Afirma, Percepta, and Envisia, targeting diseases like thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.

How do Veracyte's tests improve clinical outcomes?

Veracyte's tests provide accurate diagnoses, reducing the need for risky and unnecessary surgeries by resolving ambiguity in traditional diagnostic methods.

What recent achievements has Veracyte accomplished?

Veracyte has consistently introduced evidence that sets new standards in genomic tests, changing today's clinical practice standards.

Who benefits from Veracyte's genomic diagnostic solutions?

Both patients and physicians benefit as Veracyte's tests offer clearer diagnostic paths, improving overall patient care and reducing unnecessary medical procedures.

In which diseases does Veracyte focus its diagnostic solutions?

Veracyte focuses on diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.

What sets Veracyte apart from traditional diagnostic companies?

Veracyte leverages top-tier scientific rigor, advanced tools, and unmatched expertise to deliver unprecedented diagnostic accuracy without unnecessary surgeries.

How does Veracyte impact clinical practice standards?

Veracyte's innovative genomic tests provide evidence that fundamentally alters clinical practice standards, ensuring more accurate and less invasive diagnosis methods.

What is the significance of Veracyte's Afirma analysis?

The Afirma analysis is a key product in Veracyte's portfolio, offering accurate diagnosis for conditions like thyroid cancer, thus avoiding unnecessary surgeries.

Why is Veracyte considered a leader in genomic diagnostics?

Veracyte leads the industry due to its innovative solutions, consistent introduction of new evidence, and significant impact on improving patient care and clinical practices.

Veracyte, Inc.

Nasdaq:VCYT

VCYT Rankings

VCYT Stock Data

3.32B
76.88M
0.78%
104.58%
3.71%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
SOUTH SAN FRANCISCO